INTRODUCTION

The early and prompt diagnosis of Alzheimer’s disease (AD) crucially affects the clinical outcome.\(^1,2\) To improve the certainty of diagnosing early-stage AD, recently revised criteria incorporate atrophy of the medial temporal lobe (MTL) or hippocampus in magnetic resonance imaging (MRI) for neuronal injury and the presence of amyloid-deposition, based on the core AD symptom of progressively episodic memory impairment.\(^1,2\) Visually rating medial temporal-lobe atrophy (MTA) is a useful method in the clinical setting.\(^1,5,6\) We have proposed a T1-weighted axial Visual Rating Scale (VRS) for differentiating patients with AD from cognitively normal elderly people.

Methods

The 3,430 recruited subjects comprising 1,427 with no cognitive impairment (NC) and 2,003 AD patients were divided into age ranges of 50–59, 60–69, 70–79, and 80–89 years. Of these, 446 participants (218 in the NC group and 228 in the AD group) were chosen by random sampling for inclusion in this study. Each decade age group included 57 individuals, with the exception of 47 subjects being included in the 80- to 89-year NC group. The scores on the T1-weighted axial MTA VRS were graded by two neurologists. The cutoff values were evaluated from the area under the receiver operating characteristic curve.

Results

The optimal axial MTA VRS cutoff score from discriminating AD from NC increased with age: it was \(\geq 2\) in subjects aged 50–59, 60–69, 70–79, and 80–89 years, respectively (all \(p<0.001\)).

Conclusions

These results show that the optimal cutoff score on the axial MTA VRS for diagnosing of AD differed according to the decade age group. This information could be of practical usefulness in the clinical setting.

Key Words

medial temporal-lobe atrophy, T1-weighted axial Visual Rating Scale, cutoff score, Alzheimer’s disease.

Age-Specific Cutoff Scores on a T1-Weighted Axial Medial Temporal-Lobe Atrophy Visual Rating Scale in Alzheimer’s Disease Using Clinical Research Center for Dementia of South Korea Data

Gyeong Seon Choi, Geon Ha Kim, Ji-Hyun Choi, Ji Hyung Hwang, Eunjin Kwon, Seung Ah Lee, Kyungkeun Koo, Hee Jin Kang, Bora Yoon, Byeong C. Kim, Dong Won Yang, Duk I. Na, Hyun Jeong Han, Jae-Hong Lee, Jong Hun Kim, Kang Youn Lee, Kee Hyung Park, Kyung Won Park, SangYun Kim, Seol-Heui Han, Seong Yoon Kim, Soo Jin Yoon, So Young Moon, Yong Chul Youn, Seong Hye Choi, Jee Hyang Jeong

*Departments of Neurology, Critical Care Medicine, and Preventive Medicine, Ewha Womans University School of Medicine, Seoul, Korea
*Department of Neurology, Samsung Changan Hospital, Sungkyunkwan University School of Medicine, Cheorwon, Korea
*Department of Neurology, Konyang University Hospital, College of Medicine, Konyang University, Daejeon, Korea
*Department of Neurology, Chonnam National University Medical School, Gwangju, Korea
*Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea
*Department of Neurology, Sungkyunkwan University School of Medicine, Saifung Medical Center, Seoul, Korea
*Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Busan, Korea
*Brain Fitness Center, Bobath Memorial Hospital, Seongnam, Korea
*Department of Neurology, Myongji Hospital, Goyang, Korea
*Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
*Department of Neurology, Dementia Center, Ilan Hospital, National Health Insurance Service, Goyang, Korea
*Department of Psychiatry, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Busan, Korea
*Department of Neurology, Gachon University School of Medicine, Incheon, Korea
*Department of Neurology, Dong-A University College of Medicine and Institute of Convergence Bio-Health, Busan, Korea
*Department of Neurology, Seoul National University College of Medicine and Clinical Neuroscience Center of Seoul National University Bundang Hospital, Seongnam, Korea
*Department of Neurology, Konkuk University Medical Center, Seoul, Korea
*Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
*Department of Neurology, Eulji University College of Medicine, Daejeon, Korea
*Department of Neurology, Ajou University School of Medicine, Suwon, Korea
*Department of Neurology, Chung-Ang University College of Medicine, Seoul, Korea
*Department of Neurology, Severance Hospital, Yonsei University School of Medicine, Incheon, Korea

Received July 20, 2017
Revised November 7, 2017
Accepted November 9, 2017

Correspondence

Ji Hyang Jeong, MD, PhD
Department of Neurology, Ewha Womans University School of Medicine, Ewha Womans University Mokdong Hospital, 1071 Anyangcheon-ro, Yangpyeong-gu, Seoul 07985, Korea
Tel: +82-2-2630-2776
Fax: +82-2-2630-2612
E-mail: jeongj@ewha.ac.kr

Background and Purpose

Visual assessment of medial-temporal-lobe atrophy (MTA) has been quick, reliable, and easy to apply in routine clinical practice. However, one of the limitations in visual assessments of MTA is the lack of widely accepted age-adjusted norms and cutoff scores for MTA for a diagnosis of Alzheimer’s disease (AD). This study aimed to determine the optimal cutoff score on a T1-weighted axial MTA Visual Rating Scale (VRS) for differentiating patients with AD from cognitively normal elderly people.
While MTA is an earliest distinct pattern of brain atrophy in AD and is correlated with the disease severity, it has often also observed in the nondemented elderly population. Moreover, MTA is a rare manifestation in young patients with cognitive disorder. Previous studies have shown that brain atrophy that includes the MTL increases with age as a result of the normal aging process. Recent investigators suggested age-dependent cutoff scores on Scheltens’ MTA VRS of \( \geq 2 \) for subjects <75 years old and \( \geq 3 \) for subjects >75 years old. The present study aimed to generate practical cutoff scores on a T1-weighted axial MTA VRS for differentiating patients with AD from the cognitively normal population using data from a large cohort sample of the Clinical Research Center for Dementia of South Korea (CREDOS) study.

**METHODS**

**Subjects**

The study subjects comprised 1,427 controls with no cognitive impairment (NC) and 2003 AD patients from the CREDOS study. The CREDOS study was an observational, multidisciplinary dementia cohort from 31 centers in South Korea who participated from November 2005 until 2013. The 3,430 participants were categorized at their diagnostic visit into age groups of 50–59, 60–69, 70–79, and 80–89 years. The subjects underwent a standard assessment that included the clinical history, a neurological examination, detailed neurological tests, and an MRI examination, and laboratory tests to exclude other causes of cognitive impairment. The maximum interval between neuropsychological testing and the brain MRI examination was 3 months.

The inclusion criteria for NC were aged \( \geq 50 \) years and normal cognitive function on the Korean version of the Mini Mental State Examination (K-MMSE) and all neuropsychological tests (as described in the next section).

The inclusion criteria for the AD group were as follows: 1) criteria for probable AD based on the National Institute of Neurological and Communicative Disorders and Stroke and the AD and Related Disorders Association, and the Diagnostic and Statistical Manual of Mental Disorders (Fourth edition) criteria for probable AD, 2) age \( \geq 50 \) years, and 3) total Clinical Dementia Rating (CDR) score of 0.5 or 1. The exclusion criteria for both the NC and AD groups were as follows: 1) significant neurological or psychiatric illness, 2) significant unstable systemic disease or organ failure, and 3) severe white-matter hyperintensities (>25 mm in deep white matter or a periventricular lesion >10 mm) in T2-weighted and FLAIR MRI images, which known to be related to brain atrophy and cerebrovascular events. No patients with a clinical diagnosis of mild cognitive impairment of any subtype or a codiagnosis of AD were included in this study.

Each decade age group comprised 57 individuals (with the exception of 47 subjects being included in the 80- to 89-year NC group) chosen randomly using a list of random numbers generated in Microsoft Excel by decade age groups. In total, 446 subjects comprising 218 NC subjects and 228 of AD subjects were selected for inclusion in this study. We estimated that the sensitivity and specificity of the test would be 0.8 and 0.8, respectively. To conduct a one-sided test with the hypothesis that the sensitivity and specificity would each be 0.6 and with a significance level of 5% and a statistical power of 80%, the required number of the study subjects was 57 for each group. Since the 80- to 89-year NC group only had 47 subjects, all of them were included in the analysis.

The study was approved by the Institutional Review Board of Ewha Womans University Mokdong Hospital (IRB No. 2015-12-023-002).

**Neuropsychological tests**

All participants underwent neuropsychological tests using a standardized neuropsychological battery, the Seoul Neuropsychological Screening Battery. This battery contains tests for attention, language, praxis, four elements of Gerstmann syndrome, visuconstructive function, verbal and visual memory, and frontal/executive function. The battery used in the present study included digit span (forward and backward), the Korean version of the Boston Naming Test, the Rey-Osterrieth Complex Figure Test (copying, immediate and 20-minute delayed recall, and recognition), the Seoul Verbal Learning Test (3 learning-free recall trials of 12 words, a 20-minute delayed-recall trial for these 12 items, and a recognition test), the phonemic and semantic Controlled Oral Word Association Test, and the Stroop Test (word and color reading of 112 items during a 2-minute period). We also applied the K-MMSE, the Clinical Dementia Rating Sum of Boxes, and the Geriatric Depression Scale.

**T1-weighted axial MTA VRS**

The T1-weighted axial scans were transcribed and assembled into a numbered series in order to conceal the clinical data of the subjects. Two neurologists (one experienced and one newly trained) who were blinded to the clinical information graded MTA on the T1-weighted axial VRS by assigning a 5-grade score ranging from 0 (no atrophy) to 4 (severe atrophy). Three widths of the MTL—the hippocampus and parahippocampal gyrus, the gap of the perimesencephalic cistern, and the width of the anterior temporal horn of the lateral ventricle (labeled as A', C', and D', respectively, in Fig. 1A)—were measured on both sides (Table 1). Right and left MTA were rated separately. If the degree of MTA was asymmetric in

---

276 J Clin Neurol 2018;14(3):275-282
a participant, the side with greater atrophy was selected.

**Magnetic resonance imaging**

The MRI scans were obtained using a 1.5 Tesla (T) MRI machine (AvantoSyngo, Siemens, Erlangen, Germany) with a 12-channel head, or a 3T MRI machine (Achieva TX, Philips, the Netherlands) with a 32-channel head. Brain T1-weighted axial MRI images were acquired parallel to the line from the anterior commissure to the posterior commissure. The 1.5T T1-weighted axial images were obtained with the following parameters: slice thickness, 5.0 mm; interslice thickness, 1.65 mm; repetition time, 430 ms; echo time, 8.70 ms; flip angle, 90°; matrix size, 320×182 pixels; and field of view, 145×220 mm². The 3T T1-weighted axial images were obtained with the following parameters: slice thickness, 5.0 mm; interslice thickness, 1 mm; repetition time, 2,000 ms; echo time, 20 ms; flip angle, 90°; matrix size, 324×244 pixels; and field of view, 183×220 mm².

**Statistical analyses**

Intergroup comparisons of demographic characteristics were performed using Student’s *t*-test or the Mann-Whitney U test for continuous variables and the chi-square test for dichotomous variables. To determine an ideal cutoff value and to confirm the diagnostic performance of the cutoff scores on the axial MTA VRS in the different decade age groups, the area under the receiver operating characteristics curve (AUC) was analyzed.

**RESULTS**

**Demographic characteristics**

The clinical characteristics of subjects are presented in Table 2. Age, gender, and education level did not differ significantly...
between the NC and AD groups. The K-MMSE scores were higher and the CDR and MTA VRS scores were lower in the NC group than in AD patients.

### Decade-age-group-specific cutoff scores on the axial MTA VRS

The mean and standard-deviation scores on the T1-weighted axial MTA VRS within each decade age group are listed in Table 3. The axial MTA VRS score increased with age in both the NC and AD groups. The cutoff score indicates the lower threshold for abnormality. The sensitivity and specificity according to different axial MTA VRS cutoff scores are listed in Table 4 for each age group. AUC analyses were performed for determining the optimal cutoff scores for best discriminating between AD and NC. The results of the AUC analyses are shown in Fig. 2.

The optimal cutoff score for differentiating AD patients from the NC group was \( \geq 1 \) (sensitivity, 89.5%; specificity, 96.5%; \( p < 0.001 \); AUC, 0.934; 95% CI, 0.882–0.986) for subjects aged 50–59 years, \( \geq 1 \) (sensitivity, 89.5%; specificity, 87.7%; \( p < 0.001 \); AUC, 0.868; 95% CI, 0.799–0.938) for subjects aged 60 to 69 years, \( \geq 2 \) (sensitivity, 77.2%; specificity, 87.7%; \( p < 0.001 \); AUC, 0.845; 95% CI, 0.771–0.919) for subjects aged 70–79 years, and \( \geq 3 \) (sensitivity, 75.4%; specificity, 100%; \( p < 0.001 \); AUC, 0.919; 95% CI, 0.868–0.970) for subjects aged 80–89 years. Kappa values of the T1-weighted axial VRS were also assessed. The intrarater and interrating reliabilities of the T1-weighted axial MTA VRS scores were 0.802 and 0.786, respectively (both \( p < 0.001 \)).

### DISCUSSION

The aim of this study was to determine the optimal cutoff scores on the age-specific T1-weighted axial MTA VRS for practical use in the clinical decision tree. We found that the axial MTA VRS scores for a diagnosis of AD increased with the decade age group, as expected: the optimal score was \( \geq 1 \) for diagnosing AD in patients aged 50–69 years, \( \geq 2 \) for those aged 70–79 years, and \( \geq 3 \) for those for those aged 80–89 years. The cutoff values of the T1-weighted axial VRS score for subjects aged 50–69 years achieved a high sensitivity and specificity, enabling a clinician to differentiate AD from NC correctly and thereby improving the diagnostic accuracy in this relatively young age range. The cutoff score for subjects

| Table 2. Demographic characteristics | NC subjects (n=218) | AD patients (n=228) | \( p \) |
|-------------------------------------|-------------------|-------------------|---|
| Subjects aged 50–59 years           | 57                | 57                |   |
| Age (years)                         | 59                | 54.9±2.56         | 0.296 |
| Gender (male:female)                | 17:40             | 21:36             | 0.551 |
| Education (years)                   | 10.4±5.90         | 10.4±5.42         | 0.987 |
| K-MMSE score                        | 28.2±2.16         | 17.6±5.21         | <0.001 |
| CDR score                           | 0.4±0.23          | 0.7±0.25          | <0.001 |
| Subjects aged 60–69 years           | 57                | 57                |   |
| Age (years)                         | 64.1±2.81         | 64.7±2.99         | 0.421 |
| Gender (male:female)                | 15:42             | 25:32             | 0.077 |
| Education (years)                   | 10.2±5.35         | 8.4±4.70          | 0.195 |
| K-MMSE score                        | 27.6±2.50         | 18.8±5.62         | <0.001 |
| CDR score                           | 0.4±0.23          | 0.7±0.24          | <0.001 |
| Subjects aged 70–79 years           | 57                | 57                |   |
| Age (years)                         | 74.3±2.81         | 74.7±2.83         | 0.408 |
| Gender (male:female)                | 19:38             | 18:39             | 1.000 |
| Education (years)                   | 7.4±5.62          | 6.8±5.43          | 0.571 |
| K-MMSE score                        | 26.3±3.58         | 17.0±4.99         | <0.001 |
| CDR score                           | 0.4±0.19          | 0.8±0.25          | <0.001 |
| Subjects aged 80–89 years           | 47                | 57                |   |
| Age (years)                         | 81.9±1.82         | 82.5±2.43         | 0.156 |
| Gender (male:female)                | 19:28             | 23:34             | 1.000 |
| Education (years)                   | 6.7±5.89          | 6.9±5.28          | 0.868 |
| K-MMSE                              | 26.4±4.01         | 16.8±5.89         | <0.001 |
| CDR score                           | 0.3±0.24          | 0.8±0.25          | <0.001 |

Data are n, n, n, or mean±standard-deviation values.
AD: Alzheimer’s disease, CDR: Clinical Dementia Rating, K-MMSE: Korean version of the Mini Mental State Examination, NC: no cognitive impairment.
Choi GS et al.

JCN

aged 80–89 years showed a high specificity for detecting AD but a rather low sensitivity (75%) for differentiating between NC and AD. Therefore, in populations older than 80 years, the degree of MTA will have less effect on clinical manifestation of dementia compared to in subjects aged 50–69 years.

Assessing MTA on MRI scans using a VRS is quick and readily available. The MTA coronal VRS was proposed by Scheltens et al. in 1992, since when it has been used in numerous studies and also been modified by several researchers. The present authors have also revised this coronal scale into an axial scale through a validation study for clinical usage.

The original paper of Scheltens et al. proposed cutoff scores on the MTA VRS using T1-weighted coronal images of ≥2 for those aged <75 years and ≥3 for those aged >75 years, which was defined as an indicator of the presence of MTA suggestive of AD. Our previous study also showed that a cutoff score on the axial MTA VRS of ≥2 was the standard cut-

### Table 3. Distribution of T1-weighted axial MTA VRS scores

|                       | NC subjects (n=218) | AD patients (n=228) | p   |
|-----------------------|---------------------|---------------------|-----|
| Subjects aged 50–59 years | 0.0±0.18            | 1.1±0.56            | <0.001 |
| MTA VRS score (%)     |                     |                     |     |
| 0                     | 55 (96.5)           | 6 (10.5)            |     |
| 1                     | 2 (3.5)             | 38 (66.7)           |     |
| 2                     | 0 (0)               | 13 (22.8)           |     |
| 3                     | 0 (0)               | 0 (0)               |     |
| 4                     | 0 (0)               | 0 (0)               |     |
| Subjects aged 60–69 years | 0.1±0.39            | 1.4±0.77            | <0.001 |
| MTA VRS score (%)     |                     |                     |     |
| 0                     | 45 (78.9)           | 6 (10.5)            |     |
| 1                     | 10 (17.5)           | 27 (47.4)           |     |
| 2                     | 1 (1.8)             | 20 (35.1)           |     |
| 3                     | 1 (1.8)             | 4 (7)               |     |
| 4                     | 0 (0)               | 0 (0)               |     |
| Subjects aged 70–79 years | 1.0±0.50            | 1.9±0.66            | <0.001 |
| MTA VRS score (%)     |                     |                     |     |
| 0                     | 7 (12.3)            | 0 (0)               |     |
| 1                     | 43 (75.4)           | 13 (22.8)           |     |
| 2                     | 7 (12.3)            | 38 (66.7)           |     |
| 3                     | 0 (0)               | 4 (7)               |     |
| 4                     | 0 (0)               | 2 (3.5)             |     |
| Subjects aged 80–89 years | 1.7±0.47            | 2.8±0.49            | <0.001 |
| MTA VRS score (%)     |                     |                     |     |
| 0                     | 0 (0)               | 0 (0)               |     |
| 1                     | 16 (34)             | 0 (0)               |     |
| 2                     | 31 (66)             | 14 (24.6)           |     |
| 3                     | 0 (0)               | 41 (71.9)           |     |
| 4                     | 0 (0)               | 2 (3.5)             |     |

Data are n (%) or mean±standard-deviation values.

AD: Alzheimer’s disease, MTA: medial temporal-lobe atrophy, NC: no cognitive impairment, VRS: Visual Rating Scale.

### Table 4. SN and SP values for T1-weighted axial MTA VRS cutoff scores according to four age groups for comparing AD patients and NC subjects

| MTA VRS score | 50–59 years (n=114) | 60–69 years (n=114) | 70–79 years (n=114) | 80–89 years (n=104) |
|---------------|---------------------|---------------------|---------------------|---------------------|
|               | 57 NC, 57 AD        | 57 NC, 57 AD        | 57 NC, 57 AD        | 47 NC, 57 AD        |
| Cutoff        | SN                  | SP                  | SN                  | SP                  |
| ≥1            | 89.5*               | 96.5*               | 89.5*               | 87.7*               |
|               | 100                 | 12.3                | 100                 | 0                   |
| ≥2            | 22.8                | 100                 | 42.1                | 98.2                |
|               | 77.2*               | 87.7*               | 100                 | 34                  |
| ≥3            | 0                   | 100                 | 7                   | 100                 |
|               | 10.5                | 100                 | 3.5                 | 100                 |
| ≥4            | 0                   | 100                 | 0                   | 100                 |

*Largest combined SN and SP values in each age range.

AD: Alzheimer’s disease, MTA: medial temporal-lobe atrophy, NC: no cognitive impairment, SN: sensitivity, SP: specificity, VRS: Visual Rating Scale.
Cutoffs of T1-Axial Medial Temporal Atrophy Scale

In a more-recent study that applied Scheltens’ scale to computed tomography (CT) images, the authors suggested using cutoff scores of >1.5 for those aged <75 years and ≥2 for those aged >75 years. In another study, Pereira et al. concluded that an MTA VRS score of ≥2 (in at least one hemisphere) was considered abnormal for subjects aged <75 years, whilst a score of ≥3 (in at least one hemisphere) should be considered abnormal for subjects aged >75 years. Our study findings of cutoff scores of ≥2 for those aged 70–79 years and ≥3 for those aged 80–89 years are comparable to both of these previous studies. Our study population included AD patients with an earlier onset (<65 years of age) but had fewer patients with a late onset (>85 years of age) compared to both the studies of Scheltens et al. and Pereira et al. We therefore suggest that early-onset dementia can be diagnosed in the absence of significant MTA. In addition, some elderly subjects older than 80 years could have moderate MTA (Numerical Rating Scale score of ≥3) without significant cognitive impairment or symptoms of dementia, thereby increasing the likelihood of a false-positive AD dementia diagnosis.

Brain atrophy—especially atrophic changes in the MTL—is a useful diagnostic tool for differentiating AD from NC, but this is due to structural neuronal degeneration possibly related to tau pathology, and not a result of amyloid pathology. Memory problems such as forgetting appointments and names, difficulty looking for things, and losing familiar ways

Fig. 2. AUC for optimal medial temporal-lobe atrophy Visual Rating Scale cutoff scores in subjects aged 50–59 years (A), 60–69 years (B), 70–79 years (C), and 80–89 years (D). AUC: area under the receiver operating characteristics curve.
are an early sign of AD, but they are also common complaints in elderly individuals with normal cognition. Many previous studies showed the diagnostic certainty improved significantly—to a sensitivity and specificity of >90%—when using MTA grading on MRI scans combined with clinical manifestations. It is clear that atrophy in the MTL is a landmark neuropathological change in AD, but brain atrophy is also well known to occur in the elderly population with normal cognition. Some previous studies suggested that age-related brain atrophy occurs in the MTL even in the presence of normal cognitive function.

Our results indicate that caution is necessary when diagnosing AD in elderly patients with MTA. Although the MTA VRS score was a sensitive marker for distinguishing between AD and NC in previous studies, it might also lead to misdiagnosis. In early-onset AD with proven amyloid pathology, the MTL structures do not seem to exhibit identifiable atrophy. In addition, nondemented older adults with atrophy in the MTL are likely to be overdiagnosed as AD. In such cases the age-specific cutoff scores on the MTA VRS could be used as a secondary consideration that combines the degree of MTA and the clinical significance.

Our study was subject to several limitations. Firstly, the small number of normal controls older than 80 years and whole-brain atrophy involving the MTL at an advanced age, are likely to overestimate cutoff scores on the MTA VRS. This might have led to the low sensitivity in the oldest age group of our study. Therefore, considering the higher prevalence of AD in the elderly population, further studies involving larger numbers of normal controls older than 80 years or even 90 years are needed.

Secondly, it is possible for patients with AD-related pathology to be classified as cognitively normal when they have sufficient cognitive reserves that mitigate the development of cognitive impairment. In many such cases the cutoff scores on the MTA VRS may be increased, especially in older age groups. Thirdly, the NC group included individuals with subjective memory complaint as well as healthy normal controls without cognitive complaints, which possibly affected the VRS score and especially among those in the older age groups. Fourthly, our study might have been more powerful if we could have performed a head-to-head comparison between the axial MTA VRS and the coronal MTA VRS in the large included cohort. Unfortunately, due to the low number of coronal MRI images in the CREDOS cohort, a head-to-head comparison could not be performed. Finally, we had no evidence of amyloid pathology such as cerebrospinal fluid asy says or in positron-emission tomography to support the determination of prodromal AD and dementia due to AD.

We conclude that the optimal cutoff score on the T1-weighted axial MTA VRS for diagnosing AD varies with the decade age range. The age-specific cutoff scores proposed herein could be useful in the practical clinical setting for the differential diagnosis of AD patients and cognitively normal elderly with age-related MTA. However, further studies are needed that include sufficient subjects older than 80 years for checking the test–retest reliability, the correlation with proof of amyloid pathology, and the possible correlation with Scheltens’ coronal MTA rating in CT.

Conflicts of Interest
The authors have no financial conflicts of interest.

Acknowledgements
This study was supported by a research program to solve social issues of the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (No. 2015M3C8A8076481) and by the Original Technology Research Program for Brain Science through the National Research Foundation of Korea (NRF) funded by the Korean government (MSIP) (No. 2014M3C7A1064752).

REFERENCES
1. Shen Q, Loewenstein DA, Potter E, Zhao W, Appel J, Greig MT, et al. Volumetric and visual rating of magnetic resonance imaging scans in the diagnosis of amnestic mild cognitive impairment and Alzheimer’s disease. *Alzheimers Dement* 2011;7:e101–e108.
2. Golde TE. The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease. *Mol Neurodegener* 2009;4:8.
3. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimers Dement* 2011;7:257–262.
4. Ferreira D, Cavallin L, Larsson EM, Muehlboeck JS, Mecocci P, Vellas B, et al. Practical cut-offs for visual rating scales of medial temporal, frontal and posterior atrophy in Alzheimer’s disease and mild cognitive impairment. *J Intern Med* 2015;278:277–290.
5. Duara R, Loewenstein DA, Potter E, Appel J, Greig MT, Urs R, et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. *Neurology* 2008;71:1986–1992.
6. Harper L, Barkhof F, Fox NC, Schott JM. Using visual rating to diagnose dementia: a critical evaluation of MTA atrophy scales. *J Neurol Neurosurg Psychiatry* 2015;86:1225–1233.
7. Kim GH, Kim JE, Choi KG, Lim SM, Lee JM, Na DL, et al. T1-weighted axial visual rating scale for an assessment of medial temporal atrophy in Alzheimer’s disease. *J Alzheimers Dis* 2014;41:169–178.
8. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal aging: diagnostic value and neuropsychological correlates. *J Neurol Neurosurg Psychiatry* 1999;65:975–979.
9. Visser PJ, Verhey FR, Hofman PA, Scheltens P, Jolles J. Medial temporal lobe atrophy predicts Alzheimer’s disease in patients with minor cognitive impairment. *J Neurol Neurosurg Psychiatry* 2002;72:491–497.
10. Zhang Y, Qiu C, Lindberg O, Bronge L, Aspelin P, Backman L, et al. Acceleration of hippocampal atrophy in a non-demented elderly population: the SNAC-K study. *Int Psychogeriatr* 2010;22:14–25.
11. Wu CC, Mungas D, Peltov CI, Eberling JL, Zrelak PA, Buonocore MH, et al. Brain structure and cognition in a community sample of elderly Latinos. *Neurology* 2002;59:383–391.
12. Pereira JB, Cavallin L, Spulber G, Aguilar C, Mecocci P, Vellas B, et al.
Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs. *J Intern Med* 2014;275:317-330.

13. Choi SH, Kim S, Han SH, Na DL, Kim DK, Cheong HK, et al. Neurologic signs in relation to cognitive function in subcortical ischemic vascular dementia: a CREDOS (Clinical Research Center for Dementia of South Korea) study. *Neurosci Lett* 2012;53:839-846.

14. Barber R, Ghoklar A, Scheltens P, Ballard C, McKeith IG, O’Brien JT. MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer’s disease. *Int J Geriatr Psychiatry* 2000;15: 911-916.

15. Ahn HJ, Chin J, Park A, Lee BH, Suh MK, Seo SW, et al. Seoul Neuropsychological Screening Battery-dementia version (SNSB-D): a useful tool for assessing and monitoring cognitive impairments in dementia patients. *J Korean Med Sci* 2010;25:1071-1076.

16. Kim H, Na DL. Normative data on the Korean version of the Boston Naming Test. *J Clin Exp Neuropsychol* 1999;21:127-133.

17. Boutet C, Chupin M, Colliot O, Sarazin M, Mutlu G, Drier A, et al. Is radiological evaluation as good as computer-based volumetry to assess hippocampal atrophy in Alzheimer’s disease? *Neuroradiology* 2012;54: 1321-1330.

18. Mossman D, Somoza E. ROC curves, test accuracy, and the description of diagnostic tests. *J Neuropsychiatry Clin Neurosci* 1991;3:330-333.

19. Claus JJ, Staekenborg SS, Holl DC, Roorda JJ, Schuur J, Koster P, et al. Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: validation in a large memory clinic population. *Eur Radiol* 2017;27:3147-3155.

20. Frisoni GB, Fox NC, Jack CR Jr, Petersen RC, Xu Y, O’Brien PC, Smith GE, Ivnik RJ, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer’s disease. *Neurology* 1998;51:993-999.

21. Westman E, Cavallin L, Muehlboeck JS, Zhang Y, Mecocci P, Vellas B, et al. Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer’s disease. *PLoS One* 2011;6:e22506.

22. van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer’s disease: the case of the missing APOE ε4 allele. *Lancet Neurol* 2011;10:280-288.

23. Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, et al. One-year brain atrophy evident in healthy aging. *J Neurosci* 2009;29:15223-15231.

24. Xu J, Kobayashi S, Yamaguchi S, Iijima K, Okada K, Yamashita K. Gender effects on age-related changes in brain structure. *AJNR Am J Neuroradiol* 2000;21:112-118.

25. Schoonenboom NS, van der Flier WM, Blankenstein MA, Bouwman FH, Van Kamp GJ, Barkhof F, et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer’s disease. *Neurobiol Aging* 2008;29:669-675.